From the Division of Cardiovascular Sciences (R.F.E., N.S.D., M.F.C., M.O.), Division of Blood Diseases and Resources (M.H., T.H.M.), and Division of Lung Diseases (P.J.N., A.P., T.M.M.), National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD.
Circ Res. 2016 Jun 10;118(12):1867-71. doi: 10.1161/CIRCRESAHA.116.308550.
The National Heart, Lung, and Blood Institute (NHLBI), one of the 27 Institutes/Centers within the National Institutes of Health (NIH), has a strong interest in promoting translational research. This interest can be traced to its mission statement, which reads in part: “The NHLBI stimulates basic discoveries about the causes of disease, enables the translation of basic discoveries into clinical practice, fosters training and mentoring of emerging scientists and physicians, and communicates research advances to the public.” (www.nhlbi.gov/about/org/mission). Each year the NHLBI invests over $3 billion to support research, training and education programs to promote the prevention and treatment of heart, lung, and blood diseases and sleep disorders. More than two-thirds of this investment is allocated to investigator-initiated research spanning the continuum from discovery through preclinical and clinical studies.
美国国立卫生研究院(NIH)下属 27 个研究所/中心之一的国家心肺血液研究所(NHLBI)非常关注促进转化研究。这种兴趣可以追溯到其使命声明的一部分:“NHLBI 激发对疾病原因的基础发现,将基础发现转化为临床实践,促进新兴科学家和医生的培训和指导,并向公众传播研究进展。”(www.nhlbi.gov/about/org/mission)。每年,NHLBI 投资超过 30 亿美元,支持研究、培训和教育计划,以促进心脏、肺和血液疾病以及睡眠障碍的预防和治疗。这笔投资的三分之二以上用于支持从发现到临床前和临床研究的全过程的研究员主导的研究。